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In recent years, liquid biopsy has emerged as a potential alternative/adjunct to standard 
tissue biopsy in the diagnosis of malignancies. Current use of this technique, which tracks 
distinctive molecules released from neoplastic cells including circulating tumor cells 
(CTCs), exosomes, circulating tumor DNA (ctDNA), cell-free DNA (cfDNA) and 
miRNA, has generally been limited to determining therapies in lung cancer based on 
detectable mutations (EFGR, EML4-ALK). However, recent studies have demonstrated 
the possibility for using these molecules as more efficient prognostic and diagnostic 
biomarkers in breast, colon, rectum, lung, liver, and pancreatic cancer. Due to the need 
for standardization in sampled material (serum, plasma, urine), the types of molecules 
being investigated, and the techniques used to evaluate these molecules (ARMS/Scorpion 
assay, PNA probing, BEAM analysis, digital PCR, etc.), the idea of using liquid biopsy 
as a stand-alone method of diagnosis and prognosis requires further examination and 
collaboration among practitioners. Yet, its low invasiveness compared to standard 
methods of diagnosis as well as its capability of lending practitioners a more enhanced 
ability to track the development of a malignancy over time, particularly in patients who 
cannot tolerate repeated tissue biopsies, and to identify mutational heterogeneity in 
malignancies merits continued interest in its potential.  
 	  
